1	Title: Online Personal Training in Patients with Marfan Syndrome: A Randomized
2	Controlled Study of its Impact on Quality of Life and Physical Capacity
3	
4	Steeve Jouini ¹ , PhD, Olivier Milleron ^{2,3} , MD, Ludivine Eliahou ^{2,3} , MD, Guillaume
5	Jondeau ^{2,3,4} , MD, PhD, Damien Vitiello ^{1*} , PhD.
6	
7	1. Université Paris Cité, URP 3625-Institut des Sciences du Sport Santé de Paris (I3SP),
8	75015 Paris, France.
9	2. Centre national de référence pour le syndrome de Marfan et pathologies apparentés,
10	Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
11	3. Service de Cardiologie, Centre National de Référence Pour le Syndrome de Marfan et
12	Apparentés, AP-HP, Hôpital Bichat, 75018 Paris, France.
13	4. Université Paris Cité, Laboratory for Vascular Translational Science, INSERM U1148,
14	Hôpital Bichat-Claude-Bernard, Paris, France.
15	
16	Brief title : Training in Marfan Syndrome
17	
18	* Address for correspondence:
19	Damien VITIELLO, Université Paris Cité, URP 3625- Institut des Sciences du Sport Santé de
20	Paris (I3SP), School of Sport Sciences (STAPS), F-75015 Paris, France. Email:
21	damien.vitiello@u-paris.fr. Tel: 0033176533402.
22	
23	Total word count of the manuscript: introduction to the reference 3702 words
24	
25	

26 Abstract

Background: Marfan syndrome (MFS) is a rare genetic disorder affecting the vascular and
musculoskeletal systems. Exercise is classically contraindicated and there are no data on the
limitations associated with the syndrome and the benefits of training in this population. This
study aimed to characterise the quality of life (QoL) and physical capacity of patients with
MFS and to evaluate the benefits of a 3-month online personal training program.

Methods: MFS patients were compared with healthy subjects (H-S) at baseline. They were then randomized 1:1 into a training group (MFS-T) and a control group (MFS-C). The training consisted of 2 supervised online training sessions per week at home for 3 months, and the session program was selected based on the initial assessment. The main outcome measure was QoL as assessed by the MOS SF-36. The evolution of parameters during training was compared between MFS-T and MFS-C.

38 Results: At baseline, QoL in all dimensions was lower in MFS. Peak oxygen uptake 39 $(V \square O_2 peak)$ was also 25% lower, as was muscle elasticity. Training significantly improved 40 1) QoL (+20.2±14.3 MFS-T vs. 0.7±0.5 MFS-C), 2) V □ O₂peak (+34% MFS-T vs. 14% MFS-41 C), 3) muscle elasticity index (11.5±8.2 MFS-T vs. +1.2±1. 7 MFS-C), reduced blood 42 pressures during isometric squat (systolic -19±30 MFS-T vs. 0±6 MFS-C; diastolic -27±39 43 MFS-T vs. +2±15 MFS-C), reduced pulse wave velocity (PWV) at rest (-1.20±1.89 MFS-T 44 vs. -0.40 ± 1.61 MFS-C) and after peak exercise (-0.42 ± 0.45 MFS-T vs. 0.08 ± 0.48 MFS-C). 45 Aorta diameter remained stable in both groups (MFS-T -0.19±1.1 vs. 0.11±0.78 MFS-C). 46 After training, QoL remained lower in MFS-T than in H-S, but peak $V \square O_2$, PWV at rest and 47 after exercise were similar to those of H-S.

48 Conclusions: A 3-month online training program had a beneficial effect on QoL,49 cardiovascular and muscular parameters in MFS without affecting aortic root diameter.

50

51 Keywords: Marfan Syndrome, personalized training, exercise, e-rehabilitation.

52 Non-standard abbreviations and acronyms

- 53 1RM: One repetition maximum
- 54 MFS: Marfan syndrome
- 55 FBN1: Fibrillin-1
- 56 MFS-C: Marfan syndrome control
- 57 MFS-T: Marfan syndrome training
- 58 H-S: Healthy subjects
- 59 FB: Fat body
- 60 MM: Mass muscular
- 61 BMI: Body mass index
- 62 EF: Ejection fraction
- 63 LV: Left ventricle
- 64 GLS: Global longitudinal strain
- 65 RV: Right ventricle
- 66 PWV: Pulse wave velocity
- 67 OUES: Oxygen uptake efficiency slope
- 68 $V \square O_2$ peak: Peak oxygen uptake
- 69 VT1: First ventilatory threshold
- 70 VE: Minute ventilation
- 71 $V \square CO_2$: Volume of CO_2 produced per minute
- 72 $VE/V \square CO_2$: Ventilation/carbon dioxide output ratio
- 73 FEV1: Forced expiratory volume in one second
- 74 mET: Muscular exercise testing
- 75 HR: Heart rate
- 76 SBP: Systolic blood pressure
- 77 DBP: Diastolic blood pressure
- 78 CPET: Cardiopulmonary exercise testing
- 79 Aix: Augmentation index
- 80 TGF-B: Transforming growth factor beta
- 81 TIMP: Tissue inhibitors of metalloproteinases
- 82 MMPs: Matrix metalloproteinases
- 83 QoL: Quality of life
- 84
- 85

86 Introduction

87 Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by a pathogenic 88 variant in the gene encoding fibrillin 1 (FBN1), with more than 1,300 unique pathogenic 89 variants reported. MFS affects multiple systems, including the cardiovascular and musculoskeletal systems $^{1-4}$ and is associated with altered quality of life (OoL) 5 . The fatal 90 91 risk associated with MFS is related to aortic aneurysm expansion leading to aortic dissection 92 which can be prevented by prophylactic surgery. To date, the main medical therapy to reduce 93 the cardiovascular impact of MFS is the use of betablockers and regular medical follow-up⁶. 94 There is currently no specific exercise program available and validated, and recommendations 95 still limit physical activity to minimize the risk of aortic dilation, dissection, and possible 96 aortic rupture 6 .

97

98 The benefits of cardiopulmonary exercise training are well documented in the general 99 population and its importance is increasingly being emphasised in patients with various cardiovascular diseases, including chronic coronary heart disease^{7,8} and heart failure⁹. 100 However, there is a lack of clear data in patients with MFS. In fact, patients with MFS may 101 differ from other populations because MFS has been associated with a specific myopathy¹⁰ 102 103 and there is concern that increasing the blood pressure (BP) during exercise may increase 104 aortic root dilatation and the risk of aortic dissection. Indeed, aortic dissection has been 105 reported following isometric exercise. Deconditioning may result from this concern and may 106 also contribute to the alteration in exercise capacity and QoL in patients with MFS.

In addition, recent animal studies suggest that regular endurance exercise may be beneficial
 ^{11,12}. Therefore, a personalised online training program in combination with standard care may
 be beneficial in patients with MFS¹³.

4

110	To our knowledge, there are currently no randomized and controlled trials evaluating the
111	effects of such a program in patients with MFS and no data on the physical and physiological
112	capacity of these patients. Therefore, the aim of this study was to evaluate the effects of a 3-
113	month personalised e-training program on QoL, cardiovascular and muscular capacity in adult
114	patients with MFS. The results of this study may provide new insights into the management of
115	MFS patients and contribute to the development of more effective treatment strategies.
116	

117 Method

118

119 Study population

MFS patients: Inclusion criteria for MFS patients were: 1) adult patients (18 to 75 years of 120 121 age); 2) presence of an FBN1 pathogenic variant; 3) ability to exercise; and 4) having health 122 insurance. Exclusion criteria for MFS patients were: patients with cardiovascular disease 123 unrelated to MFS, pregnant patients, history of aortic dissection, aortic diameter > 45 mm, 124 significant aortic regurgitation, uncontrolled resting hypertension (diastolic blood pressure > 125 90 mmHg and systolic blood pressure > 140 mmHg), unavailability by telephone, 126 participation in an experiment in the 3 months prior to screening, unwillingness or inability to 127 sign the informed consent form.

128 Healthy subjects were matched for age and sex.

129

130 Study Design

MFS patients were randomized 1/1 into 2 groups: 1) MFS-C who did not benefit from the training program and were assessed at baseline and after 3 months; 2) MFS-T who followed the personalised e-training program for 3 months and were assessed at baseline and after 3 months of training.

- 135 All participants gave written informed consent before enrolment. The study complied with the
- 136 Declaration of Helsinki, the institutional ethics committee approved the study protocol
- 137 (#2020-A01751-38) and the French Society of Cardiology promoted the study.
- 138 It has been approved by Protection of Persons Committee SOUTH MEDITERRANEAN
- 139 CHU CIMIEZ HOSPITAL CS 91179 06003 NICE CEDEX 1.
- 140 The trial was prospectively registered at Clinical Trial NCT04553094
- 141
- 142 **Evaluation of patients**
- 143

144 *Quality of life assessment*

145 The Medical Outcome Study Short Form - 36 (MOS SF-36) was used to assess QoL.¹⁴.

146

147 *Echocardiography*

Patients with MFS underwent standard echocardiography and tissue Doppler imaging (Vivid 9 Dimension® ultrasound device - GE Healthcare). This study included calculation of left ventricular ejection fraction (LVEF), calculation of E/A ratio. Aortic diameters were measured at different levels (*i.e.*, ring, root, tubular aorta, arch, descending thoracic aorta and abdominal aorta). 2D strain echocardiography was also performed to assess global systolic longitudinal strain (GLS) of the LV and right ventricle (RV).

154

155 Body composition

Body composition was measured using a bioimpedance scale (Tanita Body Composition Analyzer BC-420MA). Body weight and percentage of fat mass (BF%), muscle mass (MM%) and water were assessed. Body mass index (BMI) was calculated using the following formula BMI = kg / m2, where kg is the body weight in kilograms and m2 is the height in metres squared.

161

162 Cardiopulmonary exercise training (CPET) and spirometry

At rest, before exercise, an electrocardiogram (ECG) was taken (200S-Cardioline), SBP and DBP were measured with an automatic tensiometer (METRONIK BL-6 1000) and pulse wave velocity (PWV) was measured with a Popmètre®.

166 The patients then performed an incremental exercise on the ergocycle to assess their 167 cardiorespiratory capacity. The intensity of the exercise gradually increased by 10 W/min 168 until the patients voluntarily stopped. During the exercise, the patients' expired gases were 169 continuously analysed. Peak oxygen uptake ($V \square O2peak$) was determined as the highest value 170 achieved during exercise. The ventilatory threshold 1 (VT1), the oxygen uptake efficiency 171 slope (OUES), the ratio of ventilation (VE) to carbon dioxide production (V \square CO₂) (VE/ 172 $V \square CO_2$) were calculated. Pulse wave velocity (PWV) was measured after the first ventilator 173 threshold.Heart rate (HR) and SBP And DBP were measured every 3 minutes, during the 174 CPET. If the SBP > 160 mmHg during the exercise (*i.e.*, CPET), the patient with MFS was 175 excluded from the study $^{15-18}$. 176 Pulse wave velocity (PWV) was measured again after exercise.

177 HR at the first ventilatory threshold (VT1) (HRVT1) and HR at $V \square O_2$ peak (HRpeak $V \square O_2$)

were recorded to adapt and personalise the training loads for the 3-month e-training program.

179 Peak and training HR were determined during CPET.

Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and peak
expiratory flow 25-75% (PEF25-75) were measured and FEV1/FVC was calculated.

182

183 Muscular exercise testing (mET)

184 Lower limb muscle strength and maximal force contraction were measured during a 185 countermovement jump (cm), a squat jump (cm) and a one repetition maximum (1RM) based 186 on 3 consecutive squats using a linear encoder (Bosco System Platform Chronojump). 187 They then performed an isometric bodyweight squat. During the squat, blood pressure and 188 PWV were measured (Detailed Appendix 1). 189 Two vertical jump tests were performed: the countermovement jump (CMJ) and the squat 190 jump (SJ) using the Chronojump platform. The recovery value is the difference measured 191 between the heights of the two jumps. 192 193 Pulse wave analysis 194 Pulse wave analysis was performed at rest, during exercise (*i.e.*, isometric squat and CPET) 195 and after exercise. Complete pulse wave analysis included cardiac index, reflection 196 coefficient, PWV, AIx, SBP and DBP. 197 At rest before the exercise test. A comprehensive analysis was first performed at rest in -198 the supine position. The average of the three consecutive results obtained was used for

- analysis.
- During the squat. Pulse wave velocity (PWV), systolic blood pressure (SBP) and
 diastolic blood pressure (DBP) were then measured during the 'isometric squat' while
 the patients were squatting with their knees bent at 90°, positioned on a step with their
 toes halfway over the edge of the step. One sensor was placed on the second toe and
 the other on the middle finger of the hand, while the cuff was placed on the left arm.
 Only one assessment of arterial pressure was performed and PWV was measured
 (PWV was continuously monitored).
- At rest after the CPET exercise test. Finally, the complete analysis was repeated at rest
 in the supine position after the CPET (average of 3 measurements).

8

209

210 *3-month personalized online training program for Marfan patients*

The MFS patients in the MFS-T group completed the personalised 3-month e-training program at home. The program consisted of 2 training sessions per week for a total of 24 sessions. The initial exercise intensity during the training sessions was chosen based on HRVT1 and the HR peak achieved during CPET. The patient had to remain within this intensity range.

216 Details of the training method and evaluations are described in Appendices 1 and 2. HR, DBP 217 and SBP were telemonitored during each training session and followed live either by 218 videoconference and/or by connected devices. This made it possible to check that patients 219 were achieving the target HR and to verify that SBP did not exceed 160 mmHg. Training 220 loads were adjusted weekly to achieve the best training effect based on heart rate and the RPE (rate of perceived exertion) scale ^{19,20}. Finally, patients were frequently reminded of the 221 222 training program, 3 to 4 training sessions in advance, in order to increase their adherence to 223 the program.

224

225 Statistical analyses

The study used 1:1 randomisation to form treatment and control groups to minimise potential selection bias and maximise statistical power. The sample size was determined based on the study objectives using 80% power and a 5% significance level. A mean difference of 13 points in QoL (physical component) with a standard deviation of 20 was estimated between the trained group and the control group. The minimum number of subjects required in each group was 38, but to allow for a 20% drop-out rate, the number of patients in each group was increased to 46.

233 Statistical analyses were performed using GraphPad Prism 9.4.1 software (San Diego, CA, 234 USA). One-way ANOVA was used to compare the different groups (H-S, MFS-C, MFS-T) in 235 the pre- and post-training sessions. Two-way repeated measures ANOVAs were used to 236 identify pre-post differences in the MFS-C and MFS-T groups. Different models (*i.e.*, time, 237 group and group x time interaction) were used. When significant interactions were found, 238 Tukey's post hoc test was used. To compare the effect of training on the MFS-C and MFS-T 239 groups, we analysed the difference after 3 months - baseline and used a Student's t-test. Data 240 were presented as percentages (%) or mean \pm standard deviation. Statistical significance was 241 considered when P values were ≤ 0.05 . 242 243 Results 244 A total of 105 subjects were recruited for the study (Figure 1). There were 70 MFS patients 245 and 35 healthy subjects. The characteristics of the participants are shown in Table 1. The H-S 246 were sex and age matched to the MFS patients, all of whom were receiving beta-blockers. 247 The MFS patients were heavier and taller than the H-S. Almost half of the MFS patients had 248 scoliosis and 61% had ankle sprains. The MFS patients also had dilation of the aorta and 249 global joint hypermobility. 250 251 **Baseline : Comparison of MFS patients with matched controls** 252 QoL (Table 2) was significantly different between MFS and H-S in all eight dimensions

assessed (P < 0.05). Physical function, the criterion used to calculate the power of the study,

was 55% and 68.97% lower in MFS-C and MFS-T, respectively, compared to H-S.

255 V □ O₂peak was 25% lower in MFS (MFS-C and MFS-T) compared to H-S (Figure 2a). PWV

was significantly higher in MFS immediately after CPET (Figure 2b), (P<0.001). SBP and

257 DBP were significantly higher in MFS than in H-S during isometric squat (+13% and +44%

258 respectively; Figure 2c).

259 The 1RM values were significantly lower in MFS patients compared to H-S (p < 0.001)

260 (Figure 3a).

261 The aortic root diameter was similar in the MFS-C and MFS-T groups (38.1±4.1 mm vs.

262 38.7±4.6 mm, NS) and did not increase after training (Figure 2d).

263

264 Characteristics of training sessions

265 The duration of the training session, peak and mean heart rate during the training session,

266 perceived exertion during the training session and blood pressure at the beginning, middle and

- end of the training session were recorded and are shown in Table 3.
- 268

269 Main effects of a 3-month personalized online training program in MFS patients: Δ: post -

270 pre

271 All dimensions of QOL improved significantly more in the MFS-T group than in the MFS-C

272 group after training (Table 2). The main criterion, physical function, increased by 33% in the

273 MFS-T group but remained significantly lower than in the H-S group (P < 0.0001). In

addition, a significant 31% reduction in pain was observed in the MFS-T group (P < 0.0001).

 \dot{VO}_{2peak} increased significantly more in the MFS-T group that in the MFS-C group (P<0.05)

276 (Figure 2a). Actually, after training, VO_{2peak} in MFS-T group was not significantly different

277 from $\dot{V}O_{2peak}$ in H-S (P=0.057). (26.5±4.8 ml.min⁻¹.kg⁻¹ vs. 29.4±7.6 ml.min⁻¹.kg⁻¹, NS).

278 PWV immediately after CPET decreased significantly more in the MFS-T group than in the

279 MFS-C group (5.24±0.9 m/s-1 vs. 5.69±0.74 m/s-1, P<0.0001) (Figure 2b). In fact, the post-

training PWV in the MFS-T group was close to the PWV in the H-S group (5.24±0.74 m.s-1

281 MFS-T *vs.* 4.65±0.73 m.s-1 H-S, NS).

1 RM increased significantly more in MFS-T than in MFS-C (+17 kg vs.+ 9 kg, P<0.001)

283 (Figure 3a) although it remained significantly lower than in H-S (81.9±21.9 kg vs. 133±77 kg,

- 284 P<0.05). The Elasticity Index increased significantly more in the MFS-T than in the MFS-C
- 285 $(+9.09\pm1.46 \text{ cm MFS-T } vs. 0.03\pm1.45 \text{ cm MFS-C}, P < 0.001)$ (Figure 3b).
- 286

287 Blood pressure decreased significantly more in the MFS-T than in the MFS-C during 288 isometric squat exercise (sBP -19±30 MFS-T vs. 0±6 MFS-C; dBP -27±39 MFS-T vs. +2±15 289 MFS-C; P < 0.02). SBP and dBP were lower after training in the MFS-T group than in the 290 MFS-C group (sBP: 148±15 mmHg MFS-T vs. 162±18 mmHg MFS-C, P < 0.05; dBP: 94±8 291 mmHg \pm 18 mmHg MFS-T vs. 113 \pm 20 mmHg MFS-C, P < 0.001) (Figure 2c). In the MFS-T 292 group, sBP after training was similar to that in the H-S group (148±11 mmHg vs. 143±16 293 mmHg, NS), but dBP tended to be higher (94±8 mmHg±7.37 mmHg vs. 78±14 mmHg, NS). 294 Aortic root diameters remained stable and were similar in MFS-T and MFS-C after training 295 (38.1±4.1 mm vs. 39.1±4.4 mm, NS; Figure 2d). In fact, during training, aortic diameter 296 tended to decrease in MFS-T and increase in MFS-C, but this difference was not statistically 297 significant (0.11±0.78 vs. -0.19±1.12 mm; p=0.74) (Figure 2d).

298

299 Cardiovascular and respiratory effects of a 3-month personalized e-training program in

300 MFS patients

The e-training program reduced the Aix and the reflection coefficient and increased the elasticity index in the MFS-T group compared to the MFS-C group (Table 4). It also reduced PWV at rest, during a squat and after CPET in the MFS-T group compared to the MFS-C group. The reduction in SBP with training was greater in the MFS-T group compared to the MFS-C group at rest, during a squat and during the recovery period immediately after CPET, but not during CPET. Finally, no significant differences in Tiffeneau index and PEF 25-75 were found between MFS-C and MFS-T after the exercise program.

308

309 Dropout rates

The overall dropout rate was 25%. However, it was lower in the MFS-T group (17%) than in

311 the MFS-C group (42%) (Figure 1).

312

313

314

315 Discussion

316 In this randomized and controlled study, we show that 3 months of personalised home-317 based training significantly restores the QoL of MFS patients, in particular the main criterion 318 "physical function", increases exercise capacity as measured by $V \square O_2$ peak and muscle 319 strength as measured by 1RM, and improves arterial compliance as shown by a decrease in 320 PWV. These changes can be attributed to the training program we proposed to our patient, 321 thanks to the randomized control design of our study, which made it possible to compare the 322 evolution of each parameter after the 3-month period in the 2 groups (control group, without 323 training, called MFS-C, and training group, called MFS-T). The results indicate a beneficial 324 cardiopulmonary, muscular and vascular effect of training in this population. In addition, 325 training reduced resting and exercise sBP and dBP, which may also be beneficial in the long 326 term, and no detrimental effect on aortic root diameter was observed.

In our program, each exercise session was individualised based on the CEPT at baseline. The intensity of the exercise was chosen to keep the heart rate above the heart rate observed at the first ventilator threshold during CPET and below the peak heart rate observed during CPET. The first training session was conducted in the hospital under medical supervision to monitor blood pressure and heart rate during the exercises proposed for the training sessions. All subsequent sessions were carried out at home. During the course of the program, the intensity of the home training sessions was adjusted on the basis of the perceived

exertion scale and the heart rate recorded by the patient during the previous training session.

335 This allowed for a personalised home-based program with maximum safety and efficiency.

To our knowledge, there is only one study of exercise training in people with MFS¹⁵. 336 337 In this observational study of a 3-week low-intensity exercise program in 18 MFS patients, 338 the authors reported positive effects on mental health, fatigue and exercise capacity. The 339 effect on aortic root diameter was not reported in this paper. However, a beneficial effect on the aortic root has been suggested in MFS mice 11,12 : in this mouse model, moderate-intensity 340 341 exercise reduced the growth rate of aortic diameter and the risk of aortic rupture in exercised 342 mice compared with their sedentary counterparts. These protective effects were achieved with 343 exercise at intensities between 55 and 65% of $V \square O_2$ peak.

Changes in QoL in patients with Marfan syndrome have been reported previously^{21,22}. 344 However, no intervention has been shown to improve OoL in this population. The beneficial 345 346 effects of exercise training on QoL in patients with cardiovascular disease have been well documented ^{23,24}, but data on the effects of training in patients with MFS are scarce. We show 347 348 that exercise improves all dimensions of QoL (Table 4). The dropout rate may also indirectly 349 reflect the perceived benefit of the training program by patients: in our study, the dropout rate 350 was much higher in the control group than in the training group (42% vs. 17%). Training may 351 become an important tool to limit the decline in QoL previously reported in the MFS population²². 352

The functional limitation of MFS patients is evidenced by the 25% lower $\dot{V}O_{2peak.}$ at baseline when compared to healthy subjects. This result is in keeping with two previous small studies ^{25,26}, and may partly explain the altered QoL in this population. Betablockade may participate in this decreased peak V $\square O_2$, as all MFS patients were receiving this therapy: in normal subjects²⁷, betablockade has been associated with decreased peak V $\square O_2$ by 5 to 15%, and therefore it is unlikely that betablockade does account for the entire difference between

healthy subjects and MFS patients. Beyond $V \square O_2$, a number of parameters are altered in this population, such as maximal strength and elasticity index in the muscular component of the lower limbs (already reported by 2 previous studies ^{25,26}) which may also participate in the altered QoL.

363 The training program may be beneficial beyond the increase in peak $V \square O_2$ and 364 improved QoL: the training program increased pulmonary parameters such as Tiffeneau index 365 and PEF25-75%, which increased to values similar to those of healthy subjects (Table 3). The 366 3 muscle components were also increased: 1/ increase in muscle mass, 2/ increase in muscle 367 strength, 3/ improvement in muscle elasticity. Finally, and perhaps more importantly, PWV 368 was increased at baseline, during CPET and during the recovery phase, as was the 369 augmentation index (Aix), all of which indicate more rigid arteries in the patients. Increased 370 stiffness may be responsible for greater recoil and therefore increased stress on the proximal 371 aorta, which has been associated with increased aortic root dilatation (ref) and may be related to the altered vasodilator mechanism in response to acute exercise in MFS patients ^{6,28}. 372 373 During the exercise program, PWV and Aix decreased. These effects may be beneficial in the 374 long term and are consistent with results from animal studies showing that exercise improves aortic cellular structure and, in particular, arterial compliance ^{11,12}. This beneficial effect 375 376 should be additive to the expected benefit associated with lower blood pressure resulting from 377 the lowering effect of training on blood pressure rise during exercise. Because of all these 378 indirect haemodynamic effects, one would expect that exercise would actually reduce the rate 379 of aortic root dilatation in this population. We did not see a decrease in aortic root dilatation 380 in our study, as has been reported in the mouse, but neither did we see an increase in 381 diameter. Obviously, our statistical power is too low: it took more than 4 years and more than 382 1000 subjects to suggest that sartan might possibly lead to a reduction in the rate of aortic root dilatation²⁹. 383

This benefit can be expected with a minimum of risk: during the CPET and the muscular exercise test (mET), the increase in blood pressure in MFS patients never exceeded 160 mmHg. It is important to note that, despite the limited increase in blood pressure, high heart rates were achieved during the training session, as shown in Table 3 (e.g. an average of 85% of peak HR). This suggests that vigorous intensity exercise can be proposed without risk. It is possible that the lower peak blood pressure observed during CPET at baseline (145±19.5 *vs.* 188±46.8; p<0.001) was related to the use of beta-blocker therapy in all patients.

In conclusion, MFS patients have altered QoL and exercise capacity, both of which can be improved by supervised home exercise training. We also show that many haemodynamic parameters are improved by training, which may translate into lower aortic stress and therefore limit aortic root dilatation, although we were not able to show such an effect in a short period of time in a limited population.

396

397 Study limitations

398 The program used during the training session was individualised and close monitoring of 399 heart rate and perceived exertion was carried out throughout the training period for all 400 patients. This takes time and may limit the reproducibility of the results obtained here. 401 However, a website is being set up to facilitate the adaptation of the sessions and to provide 402 all the necessary information to the patients. The size of the population is limited, but the 403 effect of training observed is impressive and unlikely to be the result of chance. Finally, the 404 population included was selected to be low-risk and the applicability of the results obtained in 405 higher-risk patients, who may benefit more from the training session, is unknown, particularly 406 because of the haemodynamic risk.

407

408 Acknowledgments

- 409 The authors dedicate this work to the patients who participated in the study and to all the
- 410 healthcare professionals in the Marfan Syndrome Reference Center in Hopital Bichat. This
- 411 study was presented at the European Days of the French Society of Cardiology in January
- 412 2022.
- 413
- 414 Sources of Funding
- 415 The study was sponsored by the Marfan Association, Multi-Fava, and Avenir Foundation.
- 416
- 417 Disclosures
- 418 The authors have no conflict of interest to report
- 419 **References**
- Rahman MAE, Haase D, Rentzsch A, Olchvary J, Schäfers H-J, Henn W, Wagenpfeil
 S, Abdul-Khaliq H. Left Ventricular Systolic Dysfunction in Asymptomatic Marfan
 Syndrome Patients Is Related to the Severity of Gene Mutation: Insights from the
 Novel Three Dimensional Speckle Tracking Echocardiography. *PLOS ONE*.
 2015;10:e0124112. doi: 10.1371/journal.pone.0124112
- Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, Pennell DJ,
 Mohiaddin RH. Evidence for Marfan cardiomyopathy. *Eur J Heart Fail*.
 2010;12:1085-1091. doi: 10.1093/eurjhf/hfq127
- Behan WMH, Longman C, Petty RKH, Comeglio P, Child AH, Boxer M, Foskett P, Harriman DGF. Muscle fibrillin deficiency in Marfan's syndrome myopathy. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74:633-638. doi: 10.1136/jnnp.74.5.633
- 432 4. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strom V, Wilhelmsen JE, Roe C.
 433 Pulmonary function, working capacity and strength in young adults with Marfan
 434 syndrome. *J Rehabil Med.* 2003;35:221-228. doi: 10.1080/16501970306095
- 435 5. Peters KF, Kong F, Horne R, Francomano CA, Biesecker BB. Living with Marfan
 436 syndrome I. Perceptions of the condition. *Clinical Genetics*. 2001;60:273-282. doi:
 437 10.1034/j.1399-0004.2001.600405.x
- 438 6. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH,
 439 Jondeau G, Evangelista A, Pyeritz RE. Marfan syndrome. *Nat Rev Dis Primers*.
 440 2021;7:64. doi: 10.1038/s41572-021-00298-7
- Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS.
 Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev.* 2016;2016:Cd001800. doi: 10.1002/14651858.CD001800.pub3
- Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet J-P, Corrado D,
 Drezner JA, Halle M, et al. 2020 ESC Guidelines on sports cardiology and exercise in
 patients with cardiovascular disease: The Task Force on sports cardiology and

exercise in patients with cardiovascular disease of the European Society of Cardiology
(ESC). *European Heart Journal*. 2021;42:17-96. doi: 10.1093/eurheartj/ehaa605

- 449 9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, 450 Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular 451 disease prevention in clinical practice: The Sixth Joint Task Force of the European 452 Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in 453 Clinical Practice (constituted by representatives of 10 societies and by invited 454 experts)Developed with the special contribution of the European Association for 455 Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-456 2381. doi: 10.1093/eurheartj/ehw106
- 457 10. Judge DP, Dietz HC. Marfan's syndrome. *Lancet*. 2005;366:1965-1976. doi:
 458 10.1016/s0140-6736(05)67789-6
- Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T,
 Rubies C, Bonorino F, Serra Peinado C, Bijnens B, Baudin J, et al. Cardiovascular
 Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an
 Animal Model. *Journal of the American Heart Association*. 2017;6:e006438. doi:
 10.1161/JAHA.117.006438
- 464 12. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, Cui JZ, van Breemen 465 C, Broderick TL, Vallejo-Elias J, et al. Mild aerobic exercise blocks elastin fiber 466 fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated 467 aortic aneurysm. JAppl Physiol (1985). 2017;123:147-160. doi: 10.1152/japplphysiol.00132.2017 468
- Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized home-based training program among patients suffering from Marfan syndrome: a pilot randomized and controlled study. *Intractable Rare Dis Res.* 2021;10:263-268. doi: 10.5582/irdr.2021.01080
- 473 14. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
 474 Conceptual framework and item selection. *Med Care*. 1992;30:473-483.
- 475 15. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J,
 476 Schroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients with
 477 Marfan syndrome: an observational pilot study. *Orphanet J Rare Dis.* 2017;12:127.
 478 doi: 10.1186/s13023-017-0679-0
- Cheng A, Owens D. Marfan syndrome, inherited aortopathies and exercise: what is the right answer? *Heart (British Cardiac Society)*. 2015;101:752-757. doi: 10.1136/heartjnl-2014-306440
- 482 17. Douard. Nouvelles recommandations pour la pratique du sport de compétition en cas
 483 d'anomalie cardiovasculaire. Archives des Maladies du Coeur et des Vaisseaux 484 Pratique. 2016;2016:27-30. doi: 10.1016/j.amcp.2016.01.010
- 18. Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic aorta. *The Annals of Thoracic Surgery*. 2003;75:1210-1214. doi: 10.1016/s0003-4975(02)04711-2
- Haddad M, Stylianides G, Djaoui L, Dellal A, Chamari K. Session-RPE Method for Training Load Monitoring: Validity, Ecological Usefulness, and Influencing Factors. *Frontiers in Neuroscience*. 2017;11. doi: 10.3389/fnins.2017.00612
- 492 20. Foster C, Florhaug JA, Franklin J, Gottschall L, Hrovatin LA, Parker S, Doleshal P,
 493 Dodge C. A new approach to monitoring exercise training. *J Strength Cond Res.*494 2001;15:109-115.
- 495 21. Rand-Hendriksen S, Johansen H, Semb SO, Geiran O, Stanghelle JK, Finset A.
 496 Health-related quality of life in Marfan syndrome: a cross-sectional study of Short

Form 36 in 84 adults with a verified diagnosis. *Genetics in Medicine: Official Journal*of the American College of Medical Genetics. 2010;12:517-524. doi:
10.1097/GIM.0b013e3181ea4c1c

- Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related
 quality of life in Marfan syndrome: a 10-year follow-up. *Health Qual Life Outcomes*.
 2020;18:376. doi: 10.1186/s12955-020-01633-4
- Hung C, Daub B, Black B, Welsh R, Quinney A, Haykowsky M. Exercise training
 improves overall physical fitness and quality of life in older women with coronary
 artery disease. *Chest.* 2004;126:1026-1031. doi: 10.1378/chest.126.4.1026
- Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Løvø KT, Gullikstad LR, Bye A,
 Skogvoll E, Wisløff U, Slørdahl SA. Aerobic interval training versus continuous
 moderate exercise after coronary artery bypass surgery: a randomized study of
 cardiovascular effects and quality of life. *American Heart Journal*. 2009;158:10311037. doi: 10.1016/j.ahj.2009.10.003
- 511 25. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strøm V, Wilhelmsen J-E, Røe C.
 512 Pulmonary function, working capacity and strength in young adults with Marfan
 513 syndrome. *Journal of Rehabilitation Medicine*. 2003;35:221-228.
- Percheron G, Fayet G, Ningler T, Le Parc J-M, Denot-Ledunois S, Leroy M, Raffestin
 B, Jondeau G. Muscle strength and body composition in adult women with Marfan
 syndrome. *Rheumatology*. 2007;46:957-962. doi: 10.1093/rheumatology/kel450
- 517 27. Tesch PA. Exercise performance and beta-blockade. *Sports Med.* 1985;2:389-412. doi: 10.2165/00007256-198502060-00002
- 519 28. Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse
 520 aorta. Role in aortic medial organization. *Lab Invest*. 1993;68:89-99.
- 521 29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin II
 522 blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med.*523 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585

564 Tables

565 Table 1 : Characterisctics of MFS patien
--

1/	MFS		H-S	P values
Variables	(n = 70)		(n=35)	
Age (years)	$33.6 \pm$	10.2	31.2 ± 11.8	3 0.34
Height (cm)	$179 \pm$	9.5	169 ± 7.85	5 <0.0001
Body weight (kg)	70.7 \pm	15.2	64.1 ± 11.6	5 0.04
BMI	$22 \pm$	6.4	21.9 ± 3.86	6 0.57
Body surface area (m ²)	1.88 \pm	0.21	1.64 ± 0.14	4 0.0008
FM (kg)	21.4 \pm	11.7	14.1 ± 7.96	5 0.003
MM (kg)	53.4 \pm	47.6	47.6 ± 8.81	0.01
Rest echocardiography				
LVEF(%)	$62.2 \pm$	7		
Aortic Ring (mm)	$23.1 \pm$	2.6		
Aortic root (mm)	$39.0 \pm$	4.7		
Tubular aorta (mm)	$29.0 \pm$	4.1		
Aortic arch (mm)	$21.1 \pm$	3.6		
Descending thoracic aorta (mm)	$18.0 \pm$	2.6		
Abdominal aorta (mm)	$15.2 \pm$	3.1		
LV GLS (%)	-19.6 ±	2.8		
Peak E/A	14.9 \pm	33		
RV GLS (%)	-35.5 ±	16.3		
Treatment				
Beta-blockers (n=)	70			
Previous Bentall (n=)	7			

Other	
Scoliosis (n=)	32
Sprained ankle (n=)	48
Pectus (n=)	27
Beighton score (mean)	5

⁵⁶⁶

567 MFS: Marfan Syndrome. H-S; Healthy Subjects. BMI: body mass index; E/A: left ventricle

early to late filling ratio; FM: fat mass; MM: muscle mass; LVEF: left ventricular ejection
fraction; LV GLS: left ventricle global longitudinal strain; RV GLS: global longitudinal
strain.

	H-S	MFS-C MFS-T			p-value				
	baseline	baseline	post	Δ pre post	baseline	post	∆ pre post	Δ pre post	ANOVA 5 groups
Physical functioning	98±2	65±25	66.07±22.9	0.71±0.50	60.68±21.6	80.97±13.2	20.2±14.3¤	0.001	0.048
Social functioning	89±16	71±31	77.38±24.5	6.84 ± 4.84	76.21±23.9	77.83±22.1	16.2±14	0.118	0.001
Role limitations: Physical	96±9	71±34	78.33±29.3	6.90±4.88	61.95±31.3	80.69±19.9	18.74±13.25	0.169	0.016
Role limitations: Emotional	90±13	88±31	83,33±34.7	-4.77±3.37	83.37±25.5	92.11±17.9	8.74±6.18	0.484	0.039
Mental health	77±12	73±21	70,43±21.4	-2.21±1.6	65.7±24.5	81.42±12.2	15.7±11.1	0.002	0.001
Energy / vitality	78±16	53±24	50,42±19.9	-2.08±1.47	48.81±20.0	75.01±16.8	26.19±18.51	0.001	0.002
Pain	94±8	69±29	64,56±21.4	-4.38±3.10	70.68±24.7	92.81±8.78	22.13±15.64	0.004	0.001
General health perceptions	83±14	51±16	55±20.2	3.57±2.52	55.65±18.9	70.56±16.9	14.91±10.54	0.009	0.041

571 Table 2: The quality of life and its evolution with training in MFS patients

572

573 H-S: healthy subjects. MFS-C: Marfan Controls. MFS-T: Marfan training. Δ pre post: difference between value at 3 months (post) and at 574 baseline (pre). At baseline MFS-C and MFS-T are significantly different from H-S for all parameters. After 3 months value changes were 575 significantly different in MFS-C an MFS

576 577 Table 3 : Key parameters during training sessions for MFS patients

	Duration of training	HR peak	HR mean	RPE	BP1	BP2	BP3
Mean	987.5	145.2	116.8	6.41	123.1/76	132.2/78.7	126.3/74.9
SD	297.7	15.08	10.71	0.89	9.66/5.16	9.52/6.75	10.91/6.11

578

Duration of training: total training time during protocol. HR peak: peak heart rate reached
during training sessions. HR means Mean heart rate during the entire training sessions. RPE:
Rated Perceived Exertion Scale measured at the end of training session. BP1 Blood pressure
before starting the training session. BP2: blood pressure at mid-session, BP3: blood pressure
at the end of training session.

584

Variables (Δ pre-post)	MFS-C			MF	S-T	P values	
LVEF(%)	-0.14	±	8.65	5.24	± 15.4	0.391	
Cardiac Index (L/min/m ²)	0.05	±	0.83	0.05	± 0.92	0.990	
Reflection coefficient (%)	-0.30	±	10.7	-12.4	± 14.5	0.020	
Alx (%)	-3.10	±	12.9	-12.2	± 9.5	0.024	
EI (cm)	0.13	±	1.52	1.89	± 1.99	0.009	
PWV at rest (m/s)	-0.02	±	0.31	-0.45	± 0.45	0.011	
PWV during squat (m/s)	0.60	±	1.02	-2.99	± 2.12	0.001	
PWV post CPET (m/s)	0.95	±	0.75	-0.87	± 1.69	0.001	
Systolic BP at rest (mmHg)	1.46	±	5.11	-2.20	± 6.13	0.070	
Systolic BP during squat (mmHg)	3.50	±	6.42	-13.5	± 16.9	0.008	
Systolic BP during CPET (mmHg)	12.9	±	30.7	-0.57	± 21.8	0.192	
Systolic BP post CPET (mmHg)	5.36	±	4.89	-3.65	± 5.46	0.001	
FEV1/FVC (%)	0.91	\pm	16.8	4.30	± 7.33	0.224	
PEF 75-25 (%)	0.19	±	0.80	4.44	± 18.10	0.445	

585586 Table 4: Cardiovascular and pulmonary effects of training in MFS patients

587

Δ: pre to post variation. Alx: augmentation index. BP: blood pressure. EI: Elasticity Index.
 LVEF: left ventricular ejection fraction. MFS-C: Marfan control. MFS-T: Marfan training. PEF:
 Peak expiratory flow. PWV: pulse wave velocity. FEV1/FVC%: Tiffeneau index.

- 591 **Figures legends :**
- 592
- 593 **Figure: 1 Flow chart.**

594

595 **Figure 2a : Peak oxygen consumption**

596 Peak oxygen consumption (V \square O₂peak) in H-S (healthy subjects), MFS-C (Marfan syndrome 597 control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). 598 Δ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to 599 MFS-C Base and MFS-T Base. ‡ p<0,05 *vs.* MFS-T Base and MFS-C Base and post. ¤: The 600 Δ 3M is significantly greater in MFS-T than in MFS-C (p<0,05).

601

602 Figure 2b Pulse wave velocity

603 2b: Pulse wave velocity (PWV) after peak exercise. in H-S (healthy subjects), MFS-C 604 (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and 605 after 3 months (3M). Δ 3M is the difference after 3 months compared to baseline. † p<0,05 606 when compared to MFS-C Base and MFS-T Base. ‡ p<0,05 *vs*. MFS-T Base and MFS-C 607 Base and post. ¤: The Δ 3M is significantly greater in MFS-T than in MFS-C (p<0,05).

608

609 *Figure 2c* Blood pressure during an isometric squat exercise

610 Blood pressure (BP = SBP and DBP) is measured during an isometric squat exercise in H-S 611 (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome 612 training), at baseline (base) and after 3 months (3M). Δ 3M is the difference after 3 months 613 compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base. ‡ p<0,05 614 *vs.* MFS-T Base and MFS-C Base and post. ¤: The Δ 3M is significantly greater in MFS-T 615 than in MFS-C (p<0,05).

616

617 Figure 2d Aortic root diameter

618 Aortic root diameter is measured during an isometric squat exercise MFS-C (Marfan 619 syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 620 months (3M). Δ 3M is the difference after 3 months compared to baseline. No significant 621 diffence were observed

622

623 Figure 3a: One repetition maximum (1RM) test for lower limbs


time of the one repetition maximum (1RM). in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). Δ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base. ‡ p<0,05 *vs*. MFS-T Base and MFS-C Base and post. ¤: The Δ 3M is significantly greater in MFS-T than in MFS-C (p<0,05).

- 629
- 630
- 631

632 Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)

the elasticity index (EI) was assessed during vertical jump tests (CMJ-SJ) . in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). Δ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base. ‡ p<0,05 vs. MFS-T Base and MFS-C Base and post. ¤: The Δ 3M is significantly greater in MFS-T than in MFS-C

638 (p<0,05).






Figure 2




Figure 2b: pulse wave velocity (PWV) after maximal exercise ok




Figure 2c: Blood pressure during an isometric squat exercise ok





Figure 2d: Aortic root diameter ok








FIGURE 3

Figure 3a : First one-repetition maximum (1RM) test for lower limbs








Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)